Pilaralisib, another pan-PI3K inhibitor, as well as the dual PI3K/mTOR inhibitor voxtalisib were each tested in combination with letrozole in phase I/II trial of AI-refractory breast cancer. Here, PIK3CA is linked to breast cancer.